Provided by Tiger Trade Technology Pte. Ltd.

First Trust Innovation Leaders ETF

40.35
+0.44001.10%
Post-market: 40.350.00000.00%19:30 EDT
Volume:25.10K
Turnover:1.01M
Market Cap:369.20M
PE:- -
High:40.38
Open:40.21
Low:39.99
Close:39.91
52wk High:41.10
52wk Low:28.19
Shares:9.15M
Float Shares:9.15M
Volume Ratio:0.51
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Alphabet Inc Class A Stock (GOOGL) Moved Up by 3.23% on Sep 30: Facts Behind the Movement

TradingKey
·
Oct 01

Google: Disallows Fixed Quota Betting Promotion in Brazil Effective Immediately

THOMSON REUTERS
·
Sep 30

Google - to Revoke Brazil Lottery and Horse Racing Certificates; Re-Application Required

THOMSON REUTERS
·
Sep 30

US Tech Giants Rally Broadly as Alphabet, Apple, Amazon Jump Over 2%; Chinese Assets Surge Late at Night; Chip Stocks Diverge; Gold and Silver Decline

Deep News
·
Sep 30

Google Introduces SynthID Bio

Reuters
·
Sep 30

US Stocks Move: Major Tech Shares Rise Broadly, Alphabet Gains Over 2%

Stock News
·
Sep 30

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Sep 30

Market Chatter: FTC to Open Probe Into Anthropic, OpenAI Over Consumer Risks

MT Newswires Live
·
Sep 30

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Sep 30

Anthropic's Potential $2 Trillion-Plus IPO Supports Robust AI Infrastructure Spending, Wedbush Says

MT Newswires Live
·
Sep 30

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Sep 30

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Sep 30

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Sep 30

Amazon call volume above normal and directionally bullish

TIPRANKS
·
Sep 30

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Sep 30

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Sep 30

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Sep 30

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Cerebras Stock Falls Again Because so Much Depends on OpenAI

Dow Jones
·
Sep 30